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Summary
Comprehensive analysis of cis-regulatory elements is key to
understanding the dynamic gene regulatory networks that
control embryonic development. While transgenic animals
represent the gold standard assay, their generation is costly,
entails significant animal usage, and in utero development
complicates time-course studies. As an alternative, embryonic
stem (ES) cells can readily be differentiated in a process that
correlates well with developing embryos. Here, we describe a
highly effective platform for enhancer assays using an Hsp68/
Venus reporter cassette that targets to the Hprt locus in
mouse ES cells. This platform combines the flexibility of
GatewayH cloning, live cell trackability of a fluorescent
reporter, low background and the advantages of single copy
insertion into a defined genomic locus. We demonstrate the
successful recapitulation of tissue-specific enhancer activity
for two cardiac and two haematopoietic enhancers. In
addition, we used this assay to dissect the functionality of
the highly conserved Ets/Ets/Gata motif in the Scl+19
enhancer, which revealed that the Gata motif is not
required for initiation of enhancer activity. We further
confirmed that Gata2 is not required for endothelial activity
of the Scl+19 enhancer using Gata22/2 Scl+19 transgenic
embryos. We have therefore established a valuable toolbox to
study gene regulatory networks with broad applicability.
 2013. Published by The Company of Biologists Ltd. This
is an Open Access article distributed under the terms of
the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution and reproduction in any
medium provided that the original work is properly
attributed.
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Introduction
The intricate process of embryonic development involves
dynamic interactions of transcription factors with gene
regulatory elements within gene regulatory networks (GRNs)
(Davidson, 2010; Pimanda and Go¨ttgens, 2010). Deciphering the
underlying mechanisms and identifying the participants of GRNs
is therefore paramount for elucidating normal developmental
processes. Key interactions involve the combinatorial binding of
transcription factors to cis-regulatory elements, and fundamental
insights can be acquired from their in silico and molecular
dissection. Comprehensive experimental interrogation requires
rigorous functional analyses for which the use of transgenic
animals has historically been considered the gold standard assay.
For the mouse model this can be expensive in animal usage
since variable copy-numbers of the transgene and integration
positional effects require multiple transgenic lines in order to
establish reproducible expression patterns. This variability can be
circumvented by exploiting embryonic stem (ES) cell lines with a
defective hypoxanthine guanine phosphoribosyl transferase 1
(Hprt) gene, since strategies that restore Hprt function enable
selection for single copy integration. As a ubiquitously expressed
gene, Hprt resides in a favourable chromatin environment and it
has been demonstrated that inclusion of tissue-specific promoter
elements into Hprt targeting constructs results in transgene
expression entirely under the control of exogenous regulatory
elements. For example, Flt-1, vWF and Tie-2 regulatory elements
inserted as single-copy reporter transgenes into the Hprt gene locus
all displayed appropriate expression patterns in transgenic mice
(Evans et al., 2000; Minami et al., 2002). However, unlike the two-
week time frame of analysing F0 transgenic embryos generated by
microinjection, the generation of Hprt transgenic reporter mice
takes a minimum of four months. Moreover, regardless of the
procedure employed for acquiring transgenic mouse embryos their
intra-uterine development complicates time-course studies.
Alternative in vitro methods are therefore highly desirable, not
only to accelerate scientific progress, but also in light of
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significant animal welfare issues associated with large-scale
generation of transgenic mouse lines. Mouse ES cells offer a
distinct advantage due to the ease with which they can be
manipulated, their ability to differentiate into cell types from all
three germ layers, and for the way in which quantitative
information of the activity of regulatory elements can be
generated during in vitro differentiation time-courses. Using a
LacZ reporter gene we have previously shown that the temporal
activity of the well-characterised Scl/Tal1 stem cell enhancer
(Scl+19), inserted into the Hprt locus correlates well with
endogenous gene expression (Smith, A. M. et al., 2008).
However, while the traditional choice of LacZ reporter genes
offers the advantage of performing histological studies with relative
ease, the complex protocols required for flow cytometric analyses
using this reporter limits the more advanced cellular experiments
that are possible with alternative reporters such as GFP.
Here, we introduce a highly effective and adaptable toolkit that
can be used to explore both wild type and perturbed enhancer
activity at high-throughput, using mouse ES cell differentiation.
We have replaced the LacZ reporter for a fluorescent reporter
gene (Venus-YFP), enabling continuous time-course experiments,
as well as substituting standard cloning strategies with GatewayH
cloning (Hartley et al., 2000). This offers a rapid pipeline for
more streamlined cloning together with a flexible and trackable
reporter system. Here, we demonstrate the reproducibility of this
approach for successful recapitulation of tissue-specific enhancer
activity in both cardiac and haematopoietic lineages. Further
advantages of using this technology become evident when we
undertake focused dissection of Gata and Ets motifs that are
known to influence the Scl+19 enhancer activity (Go¨ttgens et al.,
2002). We have gained new insights into the influence of
individual transcription factors on tissue-specific activity.
Results
Reporter construction and minimal promoter selection
To streamline flow cytometric analyses of reporter gene activity,
we replaced the LacZ reporter gene used previously (Smith, A.
M. et al., 2008) with a yellow fluorescent reporter gene, Venus
(Nagai et al., 2002) to generate an Hprt targeting cassette
containing the SV40 minimal promoter followed by the Venus
reporter. However, a high proportion (,80%) of differentiated
ES cells targeted with the resulting SV40/Venus constructs
showed YFP expression even without an enhancer (data not
shown), indicating that the SV40 minimal promoter is leaky in
this context and therefore inappropriate for our assay. Recent
large-scale transgenic studies of enhancers have made use of the
Hsp68 minimal promoter (Pennacchio et al., 2006; May et al.,
2012; Visel et al., 2013), which has long been recognised as
having a low background in enhancer assays (Kothary et al.,
1989). We therefore replaced the SV40 minimal promoter to
produce an Hsp68/Venus Hprt targeting construct and then
generated multiple independent Hsp68/Venus ES cell clones. In
contrast to the SV40/Venus clones, Hsp68/Venus clones showed
much lower background YFP (data not shown), thus suggesting
that a suitable platform for enhancer analyses with fluorescent
reporters had been established.
Cardiac enhancers display activity in ES cell-derived beating
cardiomyocytes
To test whether Hsp68/Venus constructs are effective for
assessing tissue-specific enhancer activity in live cells, we
selected previously characterised enhancers that drive reporter
gene expression in the heart. We chose two enhancers using the
VISTA Enhancer Browser (http://enhancer.lbl.gov; Visel et al.,
2007); mm75 and mm77. Enhancer mm75 is located on
chromosome 2 and is flanked by the bone morphogenetic protein
BMP7 and Tfap2d, a transcription factor that is expressed in the
developing heart (Zhao et al., 2003). Enhancer mm77 is located
on chromosome 12 between the transcription factor Cux2 and the
cardiac-specific gene Myl2 (Chien et al., 1993). Both enhancers
show strong and very specific activity in the developing heart
(Visel et al., 2007).
Using a cloning strategy that we have described previously
(Smith, A. M. et al., 2008) we produced mm75/Hsp68/Venus and
mm77/Hsp68/Venus reporter constructs and generated targeted
HM-1 ES cell lines (Fig. 1A). After differentiating ES cells for
eight days into embryoid bodies (EBs), cardiomyocytes are
formed and spontaneously start beating. We therefore
Fig. 1. Hprt targeting strategy and cardiac enhancer activity in beating
cardiomyocytes. (A) The Hprt locus in mouse HM-1 ES cells lacks the Hprt
promoter, exon 1 and exon 2. The Hprt targeting vector contains the enhancer
of interest, the Hsp68 minimal promoter and Venus fluorescent reporter gene
upstream of the human HPRT promoter, human exon 1 and mouse exon 2 and
these are all flanked by Hprt locus homology arms. Homologous recombination
of this targeting construct in HM-1 ES cells results in reconstitution of the Hprt
locus and insertion of the enhancer/Hsp68/Venus reporter upstream of the
promoter. Use of Hprt substrate analogues to select for HM-1 with deficient or
reconstituted Hprt provides a stringent selection method for selection of
correctly targeted clones. (B) Bright field (above) and fluorescent (below)
images of representative beating embryoid bodies (EBs) at day 14, from HM-1,
Hsp68/Venus control, mm75/Hsp68/Venus and mm77/Hsp68/Venus clones.
(C) Average percentage of spontaneously beating EBs that are YFP positive at
day 14 for the above clones, average of two independent differentiation
experiments.
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differentiated the ES cells for up to 14 days by which time
cardiomyocytes are prevalent. We monitored YFP expression and
found that, in agreement with expression patterns identified in the
transgenic mice (Visel et al., 2007), both enhancers show highly
specific activity in cardiomyocytes (Fig. 1B; supplementary
material Movies 1–4). In order to quantitate this, we counted
the number of spontaneously contracting EBs and then
determined the percentage of these that expressed YFP. Over
90% of beating cardiomyocytes were YFP positive for each of the
enhancer constructs (Fig. 1C). Importantly, no YFP fluorescence
was observed in spontaneously contracting EBs derived from ES
cell clones containing the enhancer-less Hsp68/Venus transgene.
Robust cardiomyocyte expression of both heart enhancers
therefore validated our in vitro enhancer assay as a potential
alternative to conventional transgenic analyses.
Increased efficiency with GatewayH cloning
Having established that the Hsp68/Venus Hprt targeting reporter
gene constructs offer a powerful alternative to study tissue-
specific enhancer activity, we next sought to improve the
efficiency of construct generation. GatewayH Cloning
Technology provides a highly efficient method of shuttling
DNA sequences between multiple vector systems (Hartley et al.,
2000) as it exploits recombination through specific attachment
(att) sites identified from lambda bacteriophage interactions
(Landy, 1989) and does not have the limitations of classic cloning
strategies involving restriction sites. We therefore inserted
Hsp68/Venus downstream of a GatewayH cassette and
transferred this cassette into the Hprt targeting vector. Simple
PCR amplification of enhancer sequences with primers that
incorporate att sites now allows the generation of pDONR vectors
from where the enhancers can be efficiently transferred into the
new GatewayH adapted Hsp68/Venus Hprt targeting vector.
A Gfi1 enhancer shows activity within haematopoietic-fated
mesoderm lineage
The transcription factor Gfi1 is expressed in multiple tissues,
including haematopoietic progenitors and stem cells, lymphoid
and myeloid cells (Karsunky et al., 2002; Hock et al., 2004;
Yu¨cel et al., 2004; Rosenbauer and Tenen, 2007; Wilson et al.,
2010a; Lancrin et al., 2012). We have previously identified an
enhancer that is located around 35 kb upstream of Gfi1 (referred
to as the Gfi1-35 enhancer) within an intron of the neighbouring
gene Evi5 (Wilson et al., 2010a). In transgenic mice this enhancer
shows specific activity in the dorsal aorta and foetal liver, in a
pattern that reflects endogenous gene expression (Wilson et al.,
2010a; Lancrin et al., 2012). As the Gfi1-35 enhancer is regulated
by six haematopoietic transcription factors that are critical for
haematopoiesis (Wilson et al., 2010b; Wilson et al., 2010a), this
element is of particular interest in terms of gene regulatory
networks that control the emergence of early blood progenitors.
We therefore inserted the Gfi1-35 element into the Hsp/Venus
vector to further analyse its function using the ES cell in vitro
differentiation model of haematopoiesis.
ES cells can readily differentiate towards the haematopoietic
lineage in a process that closely resembles in vivo development
(Keller et al., 1993), and which can be monitored using well-
characterised cell surface markers (Mitjavila-Garcia et al., 2002;
Mikkola et al., 2003). For example, the transition of Flk1 (Kdr)
positive cells of the haemangioblast towards CD41 (Itg2a)
positive haematopoietic progenitors from mouse embryonic stage
E6.5–10.5, is reflected by the distribution of these cell surface
markers during day 3–7 of ES cell differentiation (supplementary
material Fig. S1). We initially followed YFP expression by
fluorescent imaging of differentiating EBs from ES cells targeted
with Gfi1-35/Hsp/Venus (and Hsp/Venus and HM-1 controls)
from day 3 to 6 (Fig. 2A). YFP expression appeared brightest at
day 4, but continued to day 6.
To quantify this YFP expression, we disaggregated EBs and
analysed YFP expression by flow cytometry, initially at day 4. A
distinct YFP positive population was apparent above background
levels in the controls (Fig. 2B). We determined the size of the
YFP+ population by flow cytometry from day 3 to 7, and found
that it peaks at day 5 at 8–10%. However, as seen by fluorescent
microscopy, YFP expression level was highest at day 4 (Fig. 2C).
At day 4, these YFP+ EB cells are found within Flk1+CD412,
Flk+CD41+ and Flk12CD41+ populations (specifically enriched
in the later two populations), but not the CD140a+ cardiac lineage
population (Fig. 2D), consistent with the specific activity of the
Gfi1-35 enhancer in haematopoietic specification, and the
previously reported embryonic staining pattern in mouse
embryos (Wilson et al., 2010a; Lancrin et al., 2012). However,
previous analyses of the Gfi1-35 enhancer were limited to a
single time point (E11.5 of mouse embryo development), and
analyses of endogenous Gfi1 expression using knockin mice is
hampered by the limited numbers of early blood progenitors that
can be obtained from early mouse embryos. By contrast, as well
as readily permitting the generation of early blood progenitor
populations, the ES cell-based Gfi1-35 reporter system enables us
to follow the entire developmental program from embryonic
mesoderm to multi-potential blood progenitors. As a
consequence, our new Gfi1-35 enhancer reporter system
provides an unprecedented level of detail about enhancer
activity during haematopoietic specification, and suggests that
Gfi1-35 is active in Flk1+ mesoderm fated to haematopoietic
rather than cardiac specification, prior to CD41 expression,
remaining active during the specification of committed early
haematopoietic cells (Flk12CD41+).
The Scl+19 enhancer marks mesoderm with haematopoietic
and cardiac potential
To further assess the ability of the Hsp68/Venus Hprt targeting
approach to recapitulate in vivo enhancer data and dissect the
functionality of regulatory elements, we chose to concentrate on
the Scl+19 enhancer, due to its simple and highly conserved Ets/
Ets/Gata motif, well-characterised activity in transgenic embryos
and luciferase assays (Go¨ttgens et al., 2002; Go¨ttgens et al., 2004;
Silberstein et al., 2005; Spensberger et al., 2012). Scl/Tal1 is a
critical transcription factor for developmental patterning in the
mouse conceptus, necessary for primitive and definitive
haematopoiesis (Shivdasani et al., 1995; Porcher et al., 1996;
Robb et al., 1996; Barton et al., 2001; Kassouf et al., 2008) and
antagonising cardiac fate of embryonic endothelium (Ismailoglu
et al., 2008; Van Handel et al., 2012). Its correct spatiotemporal
expression is therefore critical for normal development. In
transgenic mouse embryos the Scl+19 enhancer is active in
embryonic endothelium, haemangioblasts, and committed
haematopoietic progenitors (Sa´nchez et al., 1999; Go¨ttgens
et al., 2002; Silberstein et al., 2005).
Using the GatewayH strategy outlined above we targeted the
Scl+19 enhancer into the Hprt gene locus in HM-1 ES cells.
Analysis of differentiating EBs using fluorescent imaging
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Fig. 2. See next page for legend.
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suggested the Scl+19 enhancer was active from day 3 to 6 with a large
percentage of EB cells expressing YFP during this period (Fig. 3A).
To further investigate the Scl+19 activity, we disaggregated the EBs
at day 4 and analysed YFP expression by flow cytometry. As with SV/
LacZ reporters of the Scl+19 in transgenic animals, baseline
fluorescence of enhancer-targeted cells was above the HM-1
control (Fig. 2B, Fig. 3B). However, YFP+ cells were readily
identifiable as a distinct population (Fig. 3B). We further
analysed this YFP+ population during the EB differentiation by
flow cytometry. Similar to the Gfi1-35, the YFP+ population
was seen from day 3 to 5, peaking at day 4 when 10–14% of
the differentiating cells were YFP+ (Fig. 3C). By day 6, only
background level YFP expression was seen.
We next looked at the distribution of YFP+ cells at day 4 EB,
using the surface markers Flk1, CD140a and CD41 to chart
developmental progression towards a haematopoietic fate. YFP+
cells were enriched in the Flk1+CD412, Flk1+CD41+ and
Flk12CD41+ populations during haematopoietic specification.
YFP+ cells were relatively depleted amongst CD140a+ cells
(65.6% of live cells were CD140a+ compared with 16.5% of
YFP+ cells (Fig. 3E)). While this result suggests some
enrichment for activity in the non-cardiogenic mesoderm this
was much less pronounced than for the Gfi1-35 enhancer, where
only 2.3% of YFP+ cells expressed CD140a (Fig. 2E).
Importantly, consistent differences between the Scl+19 and
Gfi1-35 enhancers were observed using multiple independent ES
cell clones, with the Scl+19 enhancer showing relatively high
activity in developmentally more immature cells.
The cellular resolution afforded by the Hsp68/Venus reporter
system therefore provides detailed developmental stage-specific
information on enhancer activity that would be very difficult to
obtain using transgenic mice.
Quantitative dissection of the Scl+19 enhancer by motif
mutations
Having demonstrated the ability to identify distinct activity
patterns for two different haematopoietic enhancers, we next
explored the utility of the Hsp68/Venus Hprt targeting approach
to compare activities of wild type and mutant enhancers.
Transcription factor binding events at regulatory elements are
predicted by the presence of conserved binding motifs and the
mutation of such motifs allows the specific activity of a class of
transcription factors to be determined. However, current methods
of mutational analysis are limited to population level luciferase
assays in transformed cell lines or qualitative analysis in
transgenic embryos. Previous analysis of the Scl+19 by these
methods suggested that mutation of any of the two highly
conserved Ets motifs or the single Gata motif results in loss of
activity (Go¨ttgens et al., 2002). Here we exploit the
aforementioned advantages of the Hprt targeting approach and
use this for quantitative analyses to compare the effects of motif
mutations on enhancer activity. The YFP reporter facilitates
analyses at the single cell level and the close resemblance of
differentiating cell types in vitro and in vivo enable us to model
the effects in the developing embryo.
To assess the contribution of the Ets and Gata motifs found
within the Scl+19 (Fig. 4A), we introduced Scl+19 motif
mutations created previously (Go¨ttgens et al., 2002) into Hsp/
Venus Hprt targeting constructs using GatewayH cloning, and
targeted these mutated enhancers to the Hprt locus in HM-1 ES
cells. As wild type Scl+19 activity peaks at day 4 of the
differentiation, we assessed the effects of the motif mutations on
YFP expression at this time point by flow cytometry (Fig. 4B).
Mutation of the Gata motif (Scl+19DGata/Hsp/Venus) reduced
the percentage of YFP+ cells from ,12% to ,5%. Mutation of
the Ets motifs (Scl+19DEts1/Hsp/Venus and Scl+19DEts2/Hsp/
Venus) individually caused a more severe reduction in the YFP+
population to 0.9 and 1.5%, respectively. Mutation of all three
motifs (Scl+19DEts1DEts2DGata/Hsp/Venus) or only both Ets
motifs simultaneously (Scl+19DEts1DEts2/Hsp/Venus) caused
complete loss of the YFP signal to background levels. In
accordance with the reduction in the size of the YFP+ populations
of the Scl+19 mutants, the mean fluorescent intensity (MFI) is
also least affected in the Scl+19DGata/Hsp/Venus (998 vs 1105
in the wild type Scl+19/Hsp/Venus), while mutation of the Ets
motifs results in an MFI that is more similar to the
Scl+19DEts1DEts2DGata/Hsp/Venus (745–903 vs 858). To
determine whether loss of the Gata motif was cell-type
specific, we analysed YFP expression within CD41/Flk1
quadrants at day 4 EB (supplementary material Fig. S2).
Relative to wild-type Scl+19 activity, YFP expression was
lost in approximately half of Flk1+CD412 and Flk1+CD41+
populations, and approximately three-quarters of Flk12CD41+
cells. This trend suggests the Gata motif may be more important,
although still not necessary, for Scl+19 activity in committed
CD41+ haematopoietic cells.
The use of single copy Venus-YFP reporter integration by this
assay therefore affords a quantitative dissection of motif
contribution to enhancer activity. Combined, these data suggest
that all three motifs within the Scl+19 are necessary for its full
activity. However, the motifs are dispensable for partial Scl+19
activity, as YFP+ cells are seen in all single motif mutation lines,
but at a lower percentage. This observation suggests that
increased transcription factor occupancy at the Scl+19 enhancer
increases the likelihood that the enhancer will become active in a
given cell. Moreover, mutation of the Gata motif caused a
relatively mild reduction compared to mutation of the Ets motifs,
suggesting that Gata factors are not critically required to activate
the Scl+19.
Gata2 is not required for endothelial activity of the Scl+19
enhancer in vivo
The observation that initiation of Scl+19 activity during ES cell
differentiation did not require an intact Gata motif was surprising
Fig. 2. Gfi1-35 activity marks haematopoietic-fated cells during embryoid body differentiation. (A) Fluorescent images of day 3–6 EBs from the representative
clones of HM-1 (top), Hsp/Venus control (middle) and Gfi1-35/Hsp/Venus (bottom) lines. (B) Representative flow cytometry plots of Venus-YFP vs side scatter
(SSC) for HM-1 (top), Hsp/Venus control (middle) and Gfi1-35/Hsp/Venus (bottom) day 4 EB cells with the YFP positive gate, and its percentage of the live
cell population, shown in red. (C) Percentage of the YFP positive population (gating shown in B) from day 3–7 for HM-1 (blue), two representative Hsp/Venus control
clones (aqua and purple) and two representative Gfi1-35/Hsp/Venus (red and orange) clones, showing average of three independent differentiation experiments 6
standard deviation. (D) Representative flow cytometry plots showing distribution of Gfi1-35/Hsp/Venus day 4 EB cells in Flk1/CD41 quadrants for all live cells (left
plot) and YFP positive cells only (right plot), with the percentage of cells in each quadrant shown in red. (E) Percentage of YFP positive cells in each of the Flk1/
CD41 quadrants of (D) for Gfi1-35/Hsp/Venus (clone 1 in red, clone 2 in orange). Average of three independent differentiation experiments 6 standard deviation.
(F) As in (D), but for Flk1/CD140a quadrants. (G) As for (E), but for Flk1/CD140a quadrants in (F).
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given that we had shown previously that Gata2 binding is
important for Scl+19 enhancer activity in haematopoietic cells
(Go¨ttgens et al., 2002; Pimanda et al., 2007). Gata2 was
originally identified as an endothelial transcription factor
(Wilson et al., 1990), and subsequently shown to be expressed
in haemangioblasts and blood stem/progenitor cells (Suzuki et al.,
2006; Lugus et al., 2007). To investigate whether Gata2 is
dispensable for induction of the Scl+19 enhancer in vivo, we
crossed transgenic mice carrying an Scl+19 enhancer LacZ
reporter (Scl-39enh/SV/lacZ) (Sa´nchez et al., 1999; Sa´nchez et al.,
2001) with Gata2+/2 mice, and then generated Gata2+/+,
Gata2+/2 or Gata22/2 E9.5 transgenic mouse embryos carrying
the Scl+19 reporter (Fig. 5A).
LacZ staining showed Scl+19 activity within the endothelium
was similar in Gata2+/2 and Gata22/2 E9.5 embryos compared
to wild-type embryo staining, thus demonstrating Gata2 is not
Fig. 3. Scl+19 activity marks haematopoietic cells and cardiac mesoderm in differentiating embryoid bodies. (A) Fluorescent images of day 3–6 EBs from a
representative Scl+19/Hsp/Venus clone. (B) Representative flow cytometry plots of Venus-YFP vs side scatter (SSC) of day 4 EBs for Scl+19/Hsp/Venus line with
the YFP positive gate, and its percentage of the live cell population, shown in red. (C) Percentage of the YFP+ population (gating shown in B) from day 3–7 for HM-1
(blue), two representative Hsp/Venus control clones (aqua and purple) and two representative Scl+19/Hsp/Venus clones (red and orange), showing the average of
three independent differentiation experiments 6 standard deviation. (D) Representative flow cytometry plots showing distribution of Scl+19/Hsp/Venus day 4 EB
cells in Flk1/CD41 quadrants for all live cells (left plot) and YFP positive cells only (right plot), with the percentage of cells in each quadrant shown in red.
(E) Percentage of YFP positive cells in each of the Flk1/CD41 quadrants of (D) for Scl+19/Hsp/Venus (clone 1 in red, clone 2 in orange). Average of three
independent differentiation experiments 6 standard deviation. (F) As in (D), but for Flk1/CD140a quadrants. (G) As for (E), but for Flk1/CD140a quadrants in (F).
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required for Scl+19 activity at this early stage of development.
Due to the embryonic lethality of Gata2 deletion, the role of
Gata2 in the activity of the Scl+19 at later stages of development,
such as during definitive haematopoiesis, could not be
determined. Nevertheless, in vivo analysis at E9.5 is consistent
with our analyses of Hsp68/Venus reporter ES cell lines, which
had shown Ets activity to be more important than Gata factors to
activate the Scl+19 enhancer.
Discussion
Here, we have validated a novel ES cell-based enhancer assay
that combines an efficient GatewayH cloning and Hprt gene
targeting strategy with the flexibility and speed of analysis
afforded by in vitro ES cell differentiation models and live cell
analysis capability via YFP reporter tracking. This robust system
additionally offers quantitative analysis of enhancer motif
mutations to dissect regulatory inputs. Beyond these
technological advantages, this assay also provides significant
financial and animal welfare benefits over current costly
transgenic mouse methodologies.
While we present here only the use of our new Hprt targeting
constructs for analysis of enhancers in cardiac and
haematopoietic lineages, it is not limited to these. Numerous
other cell types can be generated in EBs by altering the culture
conditions, including endothelium, adipocytes, skeletal and
smooth muscle, neurons, and hepatocytes, in differentiation
pathways that are thought to mimic normal development
(reviewed elsewhere (Ho¨pfl et al., 2004) and summarised in
supplementary material Table S1). We therefore believe this
system has broad applicability to analyses and dissection of
enhancer activity in many developmental pathways and provides
an attractive alternative to current transgenic mouse based
methods.
While surface marker expression during embryonic
development of the haematopoietic system has been well
defined, this is not the case for other cell types. However,
numerous tissue-specific cis-regulatory elements have been
identified during embryogenesis by the VISTA Enhancer
Browser project (Visel et al., 2007). Combination of this
knowledge with our Hsp68/Venus reporter ES cell targeting
strategy allows YFP expression to be used as a surrogate marker
for lineage commitment, providing a robust read out for
optimisation of ES cell differentiation protocols or screening
surface marker expression during organogenesis. The approach
described here could also be applied to human development
where it could find wide application in regenerative medical
research, by adaption of the targeting approach. The HPRT
(Zwaka and Thomson, 2003), ROSA26 (Irion et al., 2007) and
OCT4 (Hockemeyer et al., 2009) loci have all been successfully
targeted in human ES cells. More recently, the AAV1 site within
protein phosphatase 1 regulatory subunit 12C (PPP1R12C)
(Samulski et al., 1991) has been shown to be the preferred site
Fig. 4. Dissection of the Scl+19 enhancer by
motif mutation. (A) Sequence conservation of
the Scl+19 core region in mouse, human, dog
and opossum, with Ets motifs highlighted in
yellow and the Gata motif highlighted in green.
(B) Representative flow cytometry plots of
Venus-YFP vs side scatter (SSC) of day 4 EBs
for Scl+19/Hsp/Venus and Scl+19 mutant clones
with the YFP positive gate, its percentage of the
live cell population and mean fluorescence
intensity (MFI), shown in red.
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for gene targeting in human ES and iPS cells (Smith, J. R. et al.,
2008; Hockemeyer et al., 2009). PPP1R12C is ubiquitously
expressed in most cell types and the gene locus is in an open and
active chromatin state permitting high levels of transgene
expression. Moreover, chromatin insulators at the AAVS1 site
ensure that transgene insertion does not perturb neighbouring
gene expression and that the targeted transgene expression is
tightly controlled (Lombardo et al., 2011).
Using our novel enhancer assay, we present evidence that both
the Scl+19 and Gfi1-35 are active from the Flk1+ mesoderm stage
through to committed CD41+ haematopoietic cell stages of
haematopoietic specification. Gfi1-35 and Scl+19 enhancer
activities show similar kinetics and specificities, although the
Scl+19 is active earlier in the differentiation, with YFP+ cells seen
from day 3 of the EB differentiation while Gfi1-35 activity is only
seen from day 4 of the EB differentiation. This later activity of the
Gfi1-35 is not unsurprising considering Scl is thought to be an
important upstream regulator of this element (Wilson et al.,
2010b). While Scl plays a critical early role in haematopoiesis,
where it is necessary for haemangioblast commitment from Flk1+
mesoderm, Gfi1 is thought to play a later role in haematopoiesis,
during Flk1+CD41+ to committed CD41+ haematopoietic cells
(Lancrin et al., 2012). However, our data suggest the Gfi1-35 is
active as early as the Flk1+CD412 stage, implying the
haematopoietic transcription factor network that includes Gfi1-35
is active prior to CD41 expression during haematopoietic
specification, and may indeed mark cells fated to this lineage.
Unlike the broad haematopoietic and endothelial staining
patterning of the Scl+19 seen in Fig. 5B and (Go¨ttgens et al.,
2002), Gfi1-35 activity marks only haematopoietic clusters in the
dorsal aorta and cells in the foetal liver of developing embryos
(Lancrin et al., 2012). Consistent with this, our data show greater
specificity of Gfi1-35 activity compared to the Scl+19 in day 4
EBs for cells undergoing commitment to the haematopoietic
lineage. Furthermore, Scl+19 activity is seen in 16% of CD140a+
cells at this time point, when CD140a expression is thought to
mark prospective cardiac mesoderm and progenitors. Interestingly,
Scl is thought to play a role in patterning of cardiac mesoderm
(Van Handel et al., 2012), with Scl2/2 endocardium spontaneously
beating while Scl overexpression inhibits cardiac differentiation in
EBs (Ismailoglu et al., 2008). Our data suggest Scl+19 is active in
a subset of cardiac mesoderm, where Scl expression likely plays a
role in cardiac vs endothelial fate.
In summary, we have developed an efficient and robust enhancer
assay as an alternative to current transgenic mouse methods and
have validated its ability to recapitulate tissue-specific enhancer
activity in both cardiac and haematopoietic lineages.
Materials and Methods
Targeting vector construction
To generate a reporter gene construct containing Venus downstream of an Hsp68
promoter, the SV40 promoter was cut out of SV40/Venus/pA KS using a HindIII
restriction digest, end filling then digesting with NotI. We then cloned in the
Hsp68 promoter, which was isolated from Hsp68LacZ KS, using a BamHI digest,
followed by end filling and digesting with NotI. Subsequently this Hsp68/Venus/
PA construct was digested with SphI, end filled and digested with NotI in
preparation for cloning the cardiac enhancers mm75 and mm77, both of which were
available as HspLacZ KS reporter gene constructs (Lawrence Berkeley National
Laboratory (Visel et al., 2007)). These constructs were digested with BamHI
(mm75) or SmaI (mm77), end filled and then digested with NotI before cloning
into the linearised Hsp68/Venus/PA vector. The resulting enhancer Hsp68/Venus
reporter cassette was then cloned as a NotI-Asp718 (blunt ended) fragment into the
Hprt targeting construct pMP8NEBdeltalacZ (Misra et al., 2001) digested with
MluI (end filled) and NotI.
To adapt the cloning to Gateway technology, the reporter cassette was isolated
from the Hsp68/Venus/PA construct as a SphI blunt ended fragment and cloned
immediately downstream of the GatewayH Cassette A (Invitrogen Life
Technologies). The Hsp68/Venus/GatewayH Cassette was then cut out as a XhoI
fragment, filled and blunt end cloned into the Hprt targeting construct pSKB1
(Bronson et al., 1996), linearised with MluI and filled in. The resulting targeting
(destination) vector, pSKB1-GW-Hsp68-Venus (Hsp/Venus GatewayH) contained
the GatewayH reporter gene cassette flanked by longer Hprt homology arms than
the above (pMP8NEBdeltalacZ) targeting construct thus enabling greater
recombination efficiency.
The Gfi-35 element was PCR amplified using primers with attB sequences
(underlined) upstream of enhancer specific sequence (gfi1_35attb1F GGGGAC-
AAGTTTGTACAAAAAAGCAGGCTGAGGTTTTTAAGGCAGTGAATCAT,
gfi1_35attb1R GGGGACCACTTTGTACAAGAAAGCTGGGTCACTAGAAC-
CGAGTGCTGGA). This was then gel purified (Qiagen 78704) and used for BP
recombination into the pDONRTM221 vector (Invitrogen Life Technologies).
Successfully generated Gfi-35 pDONRTM221 vectors were recombined with the
Hsp/Venus GatewayH destination vector using LR clonase (Invitrogen Life
Technologies).
The Scl+19 wild type and mutated sequences were cloned into the Hsp/Venus
GatewayH targeting construct from SV/Luc constructs from (Go¨ttgens et al., 2002)
primers with attB sequences (underlined), GGGGACAAGTTTGTACAAAAAA-
GCAGGCTATATTAATCCCTCACTCAACAGCA and GGGGACCACTTTGT-
ACAAGAAAGCTGGGTTGAGGTAGGGCTTAGGGGG via the pDONRTM221
vector as described above. Plasmids were verified by sequencing.
The negative control vector containing the minimal promoter only (Hsp68/
Venus) was generated by annealing complementary oligos containing adjacent attB
sequences (attbF1 GGGGACAAGTTTGTACAAAAAAGCAGGCTACCCAGC-
TTTCTTGTACAAAGTGGTCCCC, attbR1 GGGGACCACTTTGTACAAGAA-
AGCTGGGTAGCCTGCTTTTTTGTACAAACTTGTCCCC). These were made
up to 800 ng/ul each in 16TE and 50 mM NaCl and heated to 95 C˚ before gradually
cooling to room temperature. The double stranded attB sequence was then used in
the recombination reactions described above in order to generate a destination vector
containing only the attB sites upstream of the Hsp68/Venus reporter. All plasmid
vectors generated as part of this study are available on request.
ES cell culture
HM-1 cells (Magin et al., 1992) were cultured feeder-free on gelatinised tissue
culture plates at 37 C˚ in 5% CO2 in ES cell medium (Knockout Dulbecco’s
Modified Eagle Medium (KO-DMEM; Invitrogen) supplemented with 15% foetal
Fig. 5. Gata2 is not required for endothelial activity of the Scl+19 enhancer
in E9.5 transgenic mouse embryos. (A) Gata2+/2 mice were crossed with
mice carrying an Scl+19 reporter (Scl-39enh/SV/lacZ) to produce Gata2+/2 Scl-
39enh/SV/lacZ mice. These were re-crossed with Gata2+/2 mice, from which
E9.5 embryos were collected and genotyped for Gata2 and Scl-39enh/SV/lacZ
phenotypes. (B) Representative whole mount images of E9.5 mouse embryos,
genotypes shown above, stained for lacZ expression using Xgal.
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bovine serum (Gibco), recombinant murine LIF (ORF Genetics), L-glutamine,
Pen/Strep and b-mercaptoethanol).
Gene targeting
Prior to gene targeting, HM-1 cells were cultured in ES cell medium supplemented
with 6-thiguanine (Sigma) for 7 days to select for Hprt-deficient cells. HM-1 cells
and linearised targeting vector were electroporated using a Gene Pulser
electroporator (BioRad) at 800 V, 3 mF, and plated at clonal density. After 24 h,
medium was replaced with ES cell medium supplemented with HAT (100 mM
hypoxanthine, 0.4 mM aminopterin, 16 mM thymidine; Sigma) to select for Hrpt
expressing clones. After 10–12 days, individual HAT-resistant ES cell colonies
were picked and expanded in ES cell medium supplemented with HT (100 mM
hypoxanthine, 16 mM thymidine; Sigma). ES cells were expanded in HT ES cell
medium for seven days and then normal ES cell medium. Correct gene targeting
was confirmed by Southern blotting or RT-PCR for expression of the reactivated
Hprt using human_HPRT_exon1_forward CAGGCGAACCTCTCGGCTTT and
mouse_Hprt_exon3_reverse GTGATGGCCTCCCATCTCCTT primers.
Cardiac differentiation
Cardiac differentiation of ES cells was performed as described (Maltsev et al.,
1993). Briefly ES cells were dissociated, washed twice and resuspended at a
concentration of 400 cells/20 ml in Dulbecco’s Modified Eagle Medium (Sigma)
supplemented with 20% FCS (Hyclone), 561025 M b-mercaptoethanol
(Invitrogen) and 16 non-essential amino acids (Invitrogen). Cardiac
differentiation by hanging drop method was initiated by pipetting 20 ml drops
containing ES cells onto the lid of a 10 cm petri dish, which was then inverted and
placed back on the dish containing PBS. Embryoid bodies were allowed to form in
hanging drops for 2 days after which they were resuspended in 10 ml of culture
medium in 10 cm petri dishes for a further 5 days. At day 7 of culture, single EBs
were plated into individual wells of a 24 well plate and cultured for an additional 7
days. At day 14 of culture, individual EBs were scored for the presence of
spontaneously contracting cells and expression of YFP.
Haematopoietic differentiation
ES cells were differentiated into EBs according to (Sroczynska et al., 2009).
Briefly, ES cells were passaged 24 h prior to differentiation and cultured in
Iscove’s Modified Dulbecco’s Medium (IMDM; HyClone) supplemented with
FBS, LIF and monothioglycerol (MTG). For the differentiation, ES cells were
dissociated, washed twice and resuspended in differentiation medium (IMDM
supplemented with 15% FBS (HyClone), 10% protein-free hybridoma medium II,
2 mM L-glutamine, 0.3 mg/ml human transferrin, 0.3 mM acorbic acid and
0.3 mM MTG). ES cells were seeded in Ultra Low Attachment 6-well dishes
(Corning) at 10,000 cells/ml in 3 ml of differentiation medium. Differentiation
medium was replaced after 5 days. EBs were harvested at required time points,
disaggregated using Trp-LE (Invitrogen), spun down and resuspended in PBS
supplemented with 5% FBS.
Fluorescence imaging
Bright field and fluorescence images were taken using a LEICA DMI 3000B
microscope with a Hamamatsu digital camera (Orca-Flash 4.0) and Optomorph
(for still images) or HCLimageLive (for timelapse imaging) software.
Flow cytometric analysis
Disaggregated EB cells were blocked using purified CD16/CD32 antibody (BD)
and stained with PE-Cy7-CD41 antibody (Biolegend), APC-Flk1 antibody (BD),
PE-CD140a (BD) or PE-CD41 (BD). Dapi (Sigma) was used as a viability stain.
Cells were analysed using a 5 laser LSRFortessa cell analyser (BD) and data
analysed using FlowJo software.
Transgenic mouse breeding and embryo analysis
All mice were housed and maintained according to UK Home Office regulations.
Gata2+/2 mice (Tsai et al., 1994) and Scl-39enh/SV/lacZ mice (Sa´nchez et al.,
1999; Sa´nchez et al., 2001) were crossed and Gata2+/2 Scl-39enh/SV/lacZ mice
confirmed by genotyping. Gata2+/2 and Gata2+/2 Scl+19/SV/lacZ mice were then
crossed and E9.5 embryos collected, genotyped and stained as described
previously (Tsai et al., 1994; Sa´nchez et al., 1999). The Scl-39enh is a 5.5 kb
genomic fragment that containing the 641 bp Scl+19 enhancer element (Sa´nchez
et al., 1999; Go¨ttgens et al., 2002). The Scl+19 element has previously been shown
to be responsible for the activity of the Scl-39enh region (Go¨ttgens et al., 2002).
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